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CASE REPORT
Repeated Plasmodium vivax malaria 
relapses in a Peruvian sailor
Adam P. McFarland1, Juan F. Sanchez2, Alejandro Mercado3, Julio A. Ventocilla2, Sofia Cavalcanti3, 
Sofia Gonzalez3 and Andres G. Lescano2,4*
Abstract 
Two Plasmodium vivax recurrences in a Peruvian sailor with weight above the 60 kg (cap for primaquine dosage) high-
light the importance of adequate radical cure weight dosage for patient treatment and control efforts, particularly 
within the military.
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Case report
A 38  year old, 76  kg, 1.68  m male Peruvian sailor pre-
sented to emergency room of the Peruvian Navy hospi-
tal in Lima on February 15, 2011. The patient reported a 
seven day history of fever, chills, and headache without 
significant past medical history. He had been deployed to 
a military base in a malaria-endemic area called VRAEM 
(Valle del Río Apurímac, Ene y Mantaro) from March 
2010 to January 2011. The patient did not receive any 
pre-deployment prophylactic anti-malarials. His physical 
examination showed 39 °C fever, but had no neurological 
or respiratory symptoms, severe malaria, jaundice, nor 
liver or kidney infection or failure. His platelet levels were 
120,000/mm3 and leukocytes at 3400 cells/µL; all other 
laboratory results were in normal ranges. The patient was 
diagnosed with Plasmodium vivax (P. vivax) malaria con-
firmed by blood smear on February 16th, and received a 
regimen of 3 days of chloroquine concurrent with 7 days 
of primaquine. He received 1 g of chloroquine on the first 
and second day of treatment, and 500  mg on the third 
day. He received 30 mg of primaquine daily for the entire 
7 days. The drug administration was in accordance with 
the Peruvian Ministry of Health standards. Treatment 
was provided under supervision by health professionals 
with complete adherence. Fever resolved by the fourth 
day of hospitalization. The final thick smear on day 7 was 
negative. The patient was discharged with no symptoms 
on March 18, 2011.
On May 20, 2011, the patient presented again to the 
emergency room with a 1-week history of similar symp-
toms. He reported no travel to other endemic areas since 
the previous hospitalization. He weighed 75 kg, had 39 °C 
fever, his platelet level was 202,000/mm3, and leukocytes 
at 4300 cells/µL. The patient had antibodies to the hepa-
titis B core antigen, but was negative for the hepatitis B 
surface antigen and other infectious diseases and para-
sites. A thick smear performed on May 20th tested posi-
tive again for P. vivax. The patient was provided the same 
treatment and dose as the initial (February) episode. His 
fever had resolved by the fourth day of hospitalization. 
The final thick smear was negative.
The patient returned a third time with similar symp-
toms in August, 2011. He reported no travel to a malaria 
endemic area since his previous hospitalization in May 
except to visit family in Pucallpa city, Peru (Ucayali 
department, 52 cases of P. vivax in 2011), during which 
he only stayed in the urban area where no malaria trans-
mission occurs, suggesting a low chance of re-infection. 
A thick smear tested positive for P. vivax. The patient 
was prescribed primaquine for 14  days at 30  mg per 
day and was released from the hospital after fully com-
pleting treatment under the supervision of Navy health 
staff. Microsatellite analysis was performed using the 
initial (February) patient blood sample and the sec-
ond recurrence (August) thick smear in order to deter-
mine the genetic relationship between episodes. The six 
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microsatellite markers tested were identical between the 
two samples (Table 1).
The periodicity of the symptoms, the patient’s low risk 
of exposure, and the homology of the molecular data sug-
gest that his second and third episodes of malaria were a 
relapse of the initial infection rather than a re-infection 
with a new parasite.
Case discussion
Primaquine is currently the only FDA approved drug to 
prevent relapses of P. vivax, as it targets the hypnozoites 
latent in hepatic cells [1, 2]. Many Ministries of Health 
in South America recommend a maximum of 30 mg/day 
for 7 days (210 mg total) establishing a maximum weight 
of 60  kg and only a week of treatment as compliance is 
low for longer time periods [3]. It has been suggested, 
however, that this total dose may be at the lower edge of 
reasonable efficacy and minimally effective [4]. Several 
studies have demonstrated failure of primaquine due to 
inadequate dosage compared to body weight [1, 5–7]. 
In this case, the maximum total dose of 210  mg recom-
mended by the Peruvian Ministry of Health [3] was not 
effective for this patient. The subject weighed 25 % over 
the 60  kg weight limit and therefore received low-dose 
regimens twice. No more relapses were observed after a 
14-day full dosage treatment. This is of particular impor-
tance for the military, as personnel tend to weigh more 
than the weight (60  kg) used to calculate the maximum 
total dosage of primaquine. Additionally, the rise of obe-
sity in malaria endemic countries could render standard 
treatment recommendations ineffective. Higher doses of 
primaquine are used in other regions, as current Cent-
ers for Disease Control and Prevention (CDC) stand-
ards advise a maximum dosage of 0.5 mg/kg/day capped 
at 60  kg (max of 30  mg/day) for no more than 14  days 
(420 mg total) in G6PD positive individuals [1]. However, 
compliance remains a critical issue. Tafenoquine, a new 
drug undergoing clinical evaluation, has been shown to be 
significantly effective in a single dose taken with chloro-
quine in preventing relapse of vivax malaria [8]. Until the 
safety and efficacy of tafenoquine can be further deter-
mined, the adoption of CDC recommendations and larger 
doses of primaquine are the only options to effectively 
treat patients and prevent relapse as well as contribute to 
the elimination of the parasite in endemic areas.
A key question in this case is whether the patient’s sub-
sequent episodes of malaria were the result of relapse of 
dormant hypnozoites or re-infection with a new strain. 
After the initial hospitalization, the patient did not travel 
to any areas with malaria transmission, making re-infec-
tion unlikely. Additionally, the strains from the Febru-
ary and August blood smears were identical based on 
molecular analysis. The Amazon Basin is a region of high 
P. vivax diversity, and homologous strains would strongly 
suggest relapse [9]. While whole genomic analysis is nec-
essary in order to completely determine if the strains are 
identical and therefore exhibiting relapse [10], re-infec-
tion is doubtful due to the low possibility of transmission, 
homologous strains between hospitalizations, and high 
genetic diversity among P. vivax species in this region. 
P. vivax exhibits geographical variation in relapse pat-
terns [11]. Historically, it has been thought that frequent 
relapsing strains originate from the tropics, and that 
strains with a long latent period originate from temper-
ate regions [12]. However, the Amazon Basin is unique in 
that it contains both long-latency and frequent relapsing 
strains, complicating attempts to characterize the pre-
dominant relapse pattern [11, 13]. Recent evidence has 
demonstrated that the majority of relapses occur within 
2–3 months of infection, with 70 % of relapses occurring 
within 5 months of initial infection [11, 14–16]. In addi-
tion, characterizing relapse patterns in malaria-endemic 
areas is inherently problematic as studies cannot com-
pletely distinguish a relapse from a new infection. True 
periodicity of relapse can most accurately be determined 
in patients with single, short exposure that minimizes the 
chance of re-infection. Travellers, including the military, 
are therefore good populations to study relapse patterns. 
In this case, the sailor did not travel to any areas where he 
could have been re-infected. His recurrent parasitaemia 
is most likely due to the reactivation of a latent strain. 
The two relapses occurring 3  months apart are most 
likely representative of the relapse pattern common in 
the Amazon Basin.
In conclusion, the frequent incidence of relapse of P. 
vivax in South America poses an important challenge for 
elimination. The 60 kg cap on patient weight and 210 mg 
maximum primaquine dose recommended in Peru and 
other South American nations may limit the efficacy nec-
essary for radical cure in individual patients and control 
Table 1 Microsatellite analysis of Plasmodium vivax infection strains
Sample Date Microsatellite markers (Chromosome position, marker ID)
3.35, v33 4.2771, v28 6.3, v30 7.67, v25 12.335, v24 14.185, v23
Initial infection Feb-11 118 87 157 101 162 270
Second recurrence Aug-11 118 87 157 101 162 270
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in the endemic population. This becomes increasingly 
important during the current epidemic of obesity, as a 
heavier patient population could negatively impact the 
management of vivax malaria and potentially other dis-
eases, as well as the effectiveness of other anti-malarial 
drugs. Until more effective radical cure drugs are licensed 
[8] or alternative parameters for dosing are explored (e.g. 
body mass index), clinicians can better prevent relapses 
in vivax malaria and support malaria control by using 
adequate primaquine dosing by weight and increasing 
the number of days of treatment up to 14 days if needed.
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